研究单位：[1]Third Affiliated Hospital,Sun Yat-Sen University[2]Peking University[3]Huazhong University of Science and Technology[4]Nanchang University[5]Huizhou Municipal Central Hospital[6]First People's Hospital,Shunde China[7]Shenzhen Third People's Hospital[8]First People's Hospital of Foshan[9]Tang-Du Hospital[10]The First Affiliated Hospital of Kunming Medical College[11]Yuebei People's Hospital
研究目的：
As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated interferon alpha and NAs.
